BRCA1 and neoplasm: Specifically, by both knocking down and inhibiting BRD4 via the novel BETi INCB054329, Wilson et al. [75] observed a substantial reduction in the expression and function of HR components, in particular BRCA1 and RAD51, both in cultured ovarian cell lines and in patient-derived xenografts; furthermore, they noticed enhanced tumor cell growth inhibition, DNA damage generation, and apoptosis when BRD4 pathway disruption was associated with treatment with Olaparib.